These findings highlight the promising potential of HDAC inhibitors in NSCLC treatment and provide a rational basis for the application of HDAC inhibitors in combination with EGFR inhibitors in clinical trials. This evidence concerns the gene HDAC9 and non-small cell lung carcinoma.